Oct 2026· Journal of Clinical Oncology· pp.
JCO2502730
· 0 citations· 24 references
Medicine
TL;DR
DE-fsHDR is a safe and effective salvage treatment for IPR and GC score is a promising prognostic tool in patients undergoing salvage local therapy for IPR and warrants further study to guide treatment intensification.
Abstract
Purpose
Prospective data on the management of intraprostatic radiorecurrence (IPR) after definitive radiotherapy (RT) and use of genomic classifiers (GC) in this setting are limited. We hypothesized that dose-escalated focal salvage high-dose-rate brachytherapy (DE-fsHDR) would be safe and effective, and that GC would risk stratify patients who may benefit from treatment intensification.
Methods
F-SHARP is a multi-institutional phase I/II trial of DE-fsHDR for IPR after any form of RT for localized prostate cancer. Patients received up to 30 Gy in 1-2 fractions. The primary objective was to determine the acute RT-related grade ≥3 CTCAE v4.03 genitourinary and GI toxicity rates. Secondary end points included all-grade toxicity, quality of life (QoL; EPIC-26 and International Prostate Symptom Score), disease control, and survival. GC analysis used a clinical-grade transcriptome assay (Veracyte, San Diego, CA). Time-to-event outcomes included biochemical progression-free survival (bPFS), radiographic progression-free survival (rPFS), local recurrence-free survival (LRFS), and metastasis-free survival (MFS).
Results
Twenty-four participants received one fraction and 38 received two fractions (N = 62). The median follow-up was 39.4 months. No acute grade 3 toxicities occurred. Two patients (3.2%) had late grade 3 toxicity. QoL changes did not meet criteria for a minimal clinically important difference. Three-year survival rates were 62.7% (bPFS), 67.5% (rPFS), 73.0% (LRFS), and 85.9% (MFS); there were no differences between fractionation groups (all P > .05). Among 31 patients with GC results, higher scores were associated with worse bPFS, rPFS, LRFS, and MFS. All patients with GC score >0.85 (n = 4) experienced biochemical, local, and metastatic recurrence.
Conclusion
DE-fsHDR is a safe and effective salvage treatment for IPR. GC score is a promising prognostic tool in patients undergoing salvage local therapy for IPR and warrants further study to guide treatment intensification.
Purpose Salvage high-dose-rate brachytherapy (sHDR-BT) is an effective option for radiorecurrent prostate cancer. This study aimed to compare the efficacy and toxicity of two sHDR-BT fractionation schedules and identify factors associated with treatment outcomes. Methods and Materials We retrospectively analyzed 223 pa...
Magdalena Stankiewicz, Agata Wilk, M. Krzempek et al.· Advances in Radiation Oncolo...· 0 citations
Findings support this approach for appropriately selected patients in routine clinical care for intermediate- and high-risk prostate cancer, as contemporary real-world evidence remains limited.
Z. El Kouzi, M. Rooney, Adam B. Samman et al.· Brachytherapy· 0 citations
OBJECTIVE
To report long-term outcomes and late toxicity after external beam radiotherapy (EBRT) with single-fraction high-dose-rate brachytherapy boost (HDR-BTB) for localized prostate cancer, examining HDR-BT sequencing and risk stratification.
METHODS AND MATERIALS
We retrospectively analyzed 607 (2012-2023) men t...
M. Choudhury, F. Adeoye, S. Nageshwaran et al.· Brachytherapy· 0 citations
HDR-BT dose escalation after initial EBRT represents a feasible non-operative treatment option for patients unfit for surgery with promising long-term local control and the incidence of late grade 3 rectal bleeding requires careful patient selection.
Alexander Kristen, N. Tselis, M. Diefenhardt et al.· Strahlentherapie und Onkolog...· 0 citations
PURPOSE
To evaluate 2-year late gastrointestinal (GI) toxicity, oncologic outcomes, and cost-effectiveness of hypofractionated concurrent chemoradiation with 44 Gy in 20 fractions (44 Gy/20F; HYPO) versus conventional fractionation (45 Gy/25F; CVRT + EMB) for locally advanced cervical cancer (LACC).
METHODS
The prima...
T. Prasartseree, P. Dankulchai, W. Sittiwong et al.· Brachytherapy· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.